Deciphering the genetic predisposition to primary sclerosing cholangitis

Seminars in Liver Disease

Volumn 31, Issue 2, 2011, Pages 188-207

  Karlsen, Tom H ^a   Kaser, Arthur ^b,c,d  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

comorbidities; genetic predisposition; major histocompatibility complex; Primary sclerosing cholangitis; T lymphocytes

Indexed keywords

INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 21; PROTEIN BCL 2;

ARTICLE; CHOLANGIOGRAPHY; CHROMOSOME 20Q; CHROMOSOME 3P; CHROMOSOME 6P; COLITIS; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; HUMAN; LIVER HISTOLOGY; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; PHENOTYPE; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ANIMALS; AUTOIMMUNITY; CHOLANGITIS, SCLEROSING; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MAJOR HISTOCOMPATIBILITY COMPLEX; PHENOTYPE; RISK ASSESSMENT; RISK FACTORS; SIGNAL TRANSDUCTION;

EID: 79955623661     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0031-1276647     Document Type: Article

References (213)

1. Karlsen T H., Schrumpf E, Boberg K M. Primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol 2010 24 5 655-666
2. European Association for the Study of the Liver. EASL clinical practice guidelines: management of cholestatic liver diseases. J Hepatol 2009 51 2 237-267
3. Chapman R, Fevery J, Kalloo A et al, American Association for the Study of Liver Diseases. Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010 51 2 660-678
4. Karlsen T H., Schrumpf E, Boberg K M. Update on primary sclerosing cholangitis. Dig Liver Dis 2010 42 6 390-400
5. Trauner M, Fickert P, Wagner M. MDR3 (ABCB4) defects: a paradigm for the genetics of adult cholestatic syndromes. Semin Liver Dis 2007 27 1 77-98
6. Beuers U, Hohenester S, de Buy Wenniger L J., Kremer A E., Jansen P L., Elferink R P. The biliary HCO(3)(-) umbrella: a unifying hypothesis on pathogenetic and therapeutic aspects of fibrosing cholangiopathies. Hepatology 2010 52 4 1489-1496
7. Lichtman S N., Keku J, Clark R L., Schwab J H., Sartor R B. Biliary tract disease in rats with experimental small bowel bacterial overgrowth. Hepatology 1991 13 4 766-772
8. Grant A J., Lalor P F., Salmi M, Jalkanen S, Adams D H. Homing of mucosal lymphocytes to the liver in the pathogenesis of hepatic complications of inflammatory bowel disease. Lancet 2002 359 9301 150-157 (Pubitemid 34112549)
9. Terjung B, Söhne J, Lechtenberg B et al. p-ANCAs in autoimmune liver disorders recognise human beta-tubulin isotype 5 and cross-react with microbial protein FtsZ. Gut 2010 59 6 808-816
10. O'Mahony C A., Vierling J M. Etiopathogenesis of primary sclerosing cholangitis. Semin Liver Dis 2006 26 1 3-21 (Pubitemid 43320723)
11. Karlsen T H., Melum E, Franke A. The utility of genome-wide association studies in hepatology. Hepatology 2010 51 5 1833-1842
12. Schrumpf E, Fausa O, F?rre O, Dobloug J H., Ritland S, Thorsby E. HLA antigens and immunoregulatory T cells in ulcerative colitis associated with hepatobiliary disease. Scand J Gastroenterol 1982 17 2 187-191 (Pubitemid 12185520)
13. Karlsen T H., Franke A, Melum E et al. Genome-wide association analysis in primary sclerosing cholangitis. Gastroenterology 2010 138 3 1102-1111
14. Ludwig J. Surgical pathology of the syndrome of primary sclerosing cholangitis. Am J Surg Pathol 1989 13 Suppl 1 43-49 (Pubitemid 19142063)
15. Fausa O, Schrumpf E, Elgjo K. Relationship of inflammatory bowel disease and primary sclerosing cholangitis. Semin Liver Dis 1991 11 1 31-39
16. Loftus E V. Jr, Harewood G C., Loftus C G. et al. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut 2005 54 1 91-96 (Pubitemid 40007225)
17. Saarinen S, Olerup O, Broom U. Increased frequency of autoimmune diseases in patients with primary sclerosing cholangitis. Am J Gastroenterol 2000 95 11 3195-3199
18. Zhernakova A, van Diemen C C., Wijmenga C. Detecting shared pathogenesis from the shared genetics of immune-related diseases. Nat Rev Genet 2009 10 1 43-55
19. Alvarez F, Berg P A., Bianchi F B. et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999 31 5 929-938 (Pubitemid 29514229)
20. Blechacz B R., Sanchez W, Gores G J. A conceptual proposal for staging ductal cholangiocarcinoma. Curr Opin Gastroenterol 2009 25 3 238-239
21. Karlsen T H., Hov J R. Genetics of cholestatic liver disease in 2010. Curr Opin Gastroenterol 2010 26 3 251-258
22. Hindorff L A., Sethupathy P, Junkins H A. et al. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc Natl Acad Sci U S A 2009 106 23 9362-9367
23. Boberg K M., Aadland E, Jahnsen J, Raknerud N, Stiris M, Bell H. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol 1998 33 1 99-103 (Pubitemid 28114077)
24. Bergquist A, Montgomery S M., Bahmanyar S et al. Increased risk of primary sclerosing cholangitis and ulcerative colitis in first-degree relatives of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2008 6 8 939-943
25. Manolio T A., Collins F S., Cox N J. et al. Finding the missing heritability of complex diseases. Nature 2009 461 7265 747-753
26. Melum E, Franke A, Schramm C et al. Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci. Nat Genet 2011 43 1 17-19
27. Clayton D G. Prediction and interaction in complex disease genetics: experience in type 1 diabetes. PLoS Genet 2009 5 7 e1000540
28. Lindor K D., Wiesner R H., Colwell L J., Steiner B, Beaver S, LaRusso N F. The combination of prednisone and colchicine in patients with primary sclerosing cholangitis. Am J Gastroenterol 1991 86 1 57-61
29. Van Thiel D H., Carroll P, Abu-Elmagd K et al. Tacrolimus (FK 506), a treatment for primary sclerosing cholangitis: results of an open-label preliminary trial. Am J Gastroenterol 1995 90 3 455-459
30. Wiesner R H., Steiner B, LaRusso N F. et al. A controlled clinical trial evaluating cyclosporine in the treatment of primary sclerosing cholangitis. Hepatology 1991 14 A64 (Abstract)
31. Sandborn W J., Wiesner R H., Tremaine W J., Larusso N F. Ulcerative colitis disease activity following treatment of associated primary sclerosing cholangitis with cyclosporin. Gut 1993 34 2 242-246 (Pubitemid 23049120)
32. Cullen S N., Chapman R W. The medical management of primary sclerosing cholangitis. Semin Liver Dis 2006 26 1 52-61 (Pubitemid 43320727)
33. Boberg K M., Egeland T, Schrumpf E. Long-term effect of corticosteroid treatment in primary sclerosing cholangitis patients. Scand J Gastroenterol 2003 38 9 991-995 (Pubitemid 37158028)
34. Lango Allen H, Estrada K, Lettre G et al. Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature 2010 457 832-838
35. Traherne J A. Human MHC architecture and evolution: implications for disease association studies. Int J Immunogenet 2008 35 3 179-192 (Pubitemid 351678693)
36. Horton R, Wilming L, Rand V et al. Gene map of the extended human MHC. Nat Rev Genet 2004 5 12 889-899 (Pubitemid 39564252)
37. de Bakker P I., McVean G, Sabeti P C. et al. A high-resolution HLA and SNP haplotype map for disease association studies in the extended human MHC. Nat Genet 2006 38 10 1166-1172 (Pubitemid 44470362)
38. Sollid L M., Markussen G, Ek J, Gjerde H, Vartdal F, Thorsby E. Evidence for a primary association of celiac disease to a particular HLA-DQ alpha/beta heterodimer. J Exp Med 1989 169 1 345-350 (Pubitemid 19035567)
39. Todd J A., Bell J I., McDevitt H O. HLA-DQ beta gene contributes to susceptibility and resistance to insulin-dependent diabetes mellitus. Nature 1987 329 6140 599-604 (Pubitemid 17140111)
40. Oksenberg J R., Barcellos L F., Cree B A. et al. Mapping multiple sclerosis susceptibility to the HLA-DR locus in African Americans. Am J Hum Genet 2004 74 1 160-167 (Pubitemid 38085247)
41. Schlosstein L, Terasaki P I., Bluestone R, Pearson C M. High association of an HL-A antigen, W27, with ankylosing spondylitis. N Engl J Med 1973 288 14 704-706
42. Nair R P., Stuart P E., Nistor I et al. Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene. Am J Hum Genet 2006 78 5 827-851
43. Lie B A., Thorsby E. Several genes in the extended human MHC contribute to predisposition to autoimmune diseases. Curr Opin Immunol 2005 17 5 526-531 (Pubitemid 41213322)
44. Nejentsev S, Howson J M., Walker N M. et al, Wellcome Trust Case Control Consortium. Localization of type 1 diabetes susceptibility to the MHC class I genes HLA-B and HLA-A. Nature 2007 450 7171 887-892 (Pubitemid 350231332)
45. Fernando M M., Stevens C R., Walsh E C. et al. Defining the role of the MHC in autoimmunity: a review and pooled analysis. PLoS Genet 2008 4 4 e1000024
46. Rioux J D., Goyette P, Vyse T J. et al, International MHC and Autoimmunity Genetics Network. Mapping of multiple susceptibility variants within the MHC region for 7 immune-mediated diseases. Proc Natl Acad Sci U S A 2009 106 44 18680-18685
47. The International HIV Controllers Study. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 2010 330 6010 1551-1557
48. Karlsen T H., Boberg K M., Olsson M et al. Particular genetic variants of ligands for natural killer cell receptors may contribute to the HLA associated risk of primary sclerosing cholangitis. J Hepatol 2007 46 5 899-906 (Pubitemid 46529047)
49. Hov J R., Lleo A, Selmi C et al. Genetic associations in Italian primary sclerosing cholangitis: heterogeneity across Europe defines a critical role for HLA-C. J Hepatol 2010 52 5 712-717
50. Hov J R., Boberg K M., Karlsen T H. Autoantibodies in primary sclerosing cholangitis. World J Gastroenterol 2008 14 24 3781-3791
51. van Heel D A., Franke L, Hunt K A. et al. A genome-wide association study for celiac disease identifies risk variants in the region harboring IL2 and IL21. Nat Genet 2007 39 7 827-829 (Pubitemid 47014494)
52. Festen E A., Goyette P, Scott R et al. Genetic variants in the region harbouring IL2/IL21 associated with ulcerative colitis. Gut 2009 58 6 799-804
53. Hollis-Moffatt J E., Chen-Xu M, Topless R et al. Only one independent genetic association with rheumatoid arthritis within the KIAA1109-TENR-IL2-IL21 locus in Caucasian sample sets: confirmation of association of rs6822844 with rheumatoid arthritis at a genome-wide level of significance. Arthritis Res Ther 2010 12 3 R116
54. Todd J A., Walker N M., Cooper J D. et al, Genetics of Type 1 Diabetes in Finland Wellcome Trust Case Control Consortium. Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat Genet 2007 39 7 857-864 (Pubitemid 47018195)
55. Janse M, Lamberts L E., Franke L et al. Three ulcerative colitis susceptibility loci are associated with primary sclerosing cholangitis and indicate a role for IL2, REL and CARS9. [Epub ahead of print]
56. Vella A, Cooper J D., Lowe C E. et al. Localization of a type 1 diabetes locus in the IL2RA/CD25 region by use of tag single-nucleotide polymorphisms. Am J Hum Genet 2005 76 5 773-779 (Pubitemid 40563099)
57. Franke A, McGovern D P., Barrett J C. et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet 2010 42 12 1118-1125
58. Anderson C A., Boucher G, Lees C W. et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet 2011 43 3 246-252
59. Qu H Q., Bradfield J P., Blisle A, Grant S F., Hakonarson H, Polychronakos C, Type I Diabetes Genetics Consortium. The type I diabetes association of the IL2RA locus. Genes Immun 2009 10 Suppl 1 S42-S48
60. Lowe C E., Cooper J D., Brusko T et al. Large-scale genetic fine mapping and genotype-phenotype associations implicate polymorphism in the IL2RA region in type 1 diabetes. Nat Genet 2007 39 9 1074-1082 (Pubitemid 47340651)
61. Perera D, Stankovich J, Butzkueven H et al. Fine mapping of multiple sclerosis susceptibility genes provides evidence of allelic heterogeneity at the IL2RA locus. J Neuroimmunol 2009 211 1-2 105-109
62. Qu H Q., Verlaan D J., Ge B et al. A cis-acting regulatory variant in the IL2RA locus. J Immunol 2009 183 8 5158-5162
63. Dendrou C A., Plagnol V, Fung E et al. Cell-specific protein phenotypes for the autoimmune locus IL2RA using a genotype-selectable human bioresource. Nat Genet 2009 41 9 1011-1015
64. Malek T R., Castro I. Interleukin-2 receptor signaling: at the interface between tolerance and immunity. Immunity 2010 33 2 153-165
65. Yamanouchi J, Rainbow D, Serra P et al. Interleukin-2 gene variation impairs regulatory T cell function and causes autoimmunity. Nat Genet 2007 39 3 329-337 (Pubitemid 46328484)
66. Wakabayashi K, Lian Z X., Moritoki Y et al. IL-2 receptor alpha( / ) mice and the development of primary biliary cirrhosis. Hepatology 2006 44 5 1240-1249 (Pubitemid 44748374)
67. Sadlack B, Merz H, Schorle H, Schimpl A, Feller A C., Horak I. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 1993 75 2 253-261 (Pubitemid 23320289)
68. Willerford D M., Chen J, Ferry J A., Davidson L, Ma A, Alt F W. Interleukin-2 receptor alpha chain regulates the size and content of the peripheral lymphoid compartment. Immunity 1995 3 4 521-530
69. Hsu W, Zhang W, Tsuneyama K et al. Differential mechanisms in the pathogenesis of autoimmune cholangitis versus inflammatory bowel disease in interleukin-2Ralpha( / ) mice. Hepatology 2009 49 1 133-140
70. Zhang W, Sharma R, Ju S T. et al. Deficiency in regulatory T cells results in development of antimitochondrial antibodies and autoimmune cholangitis. Hepatology 2009 49 2 545-552
71. Fontenot J D., Rudensky A Y. A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3. Nat Immunol 2005 6 4 331-337 (Pubitemid 41716769)
72. Hirschfield G M., Liu X, Xu C et al. Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. N Engl J Med 2009 360 24 2544-2555
73. Hirschfield G M., Liu X, Han Y et al. Variants at IRF5-TNPO3, 17q12-21 and MMEL1 are associated with primary biliary cirrhosis. Nat Genet 2010 42 8 655-657
74. Liu X, Invernizzi P, Lu Y et al. Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. Nat Genet 2010 42 8 658-660
75. Irie J, Wu Y, Wicker L S. et al. NOD.c3c4 congenic mice develop autoimmune biliary disease that serologically and pathogenetically models human primary biliary cirrhosis. J Exp Med 2006 203 5 1209-1219 (Pubitemid 43736591)
76. Coquet J M., Kyparissoudis K, Pellicci D G. et al. IL-21 is produced by NKT cells and modulates NKT cell activation and cytokine production. J Immunol 2007 178 5 2827-2834 (Pubitemid 46333160)
77. Spolski R, Leonard W J. Interleukin-21: basic biology and implications for cancer and autoimmunity. Annu Rev Immunol 2008 26 57-79 (Pubitemid 351600371)
78. Parrish-Novak J, Dillon S R., Nelson A et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 2000 408 6808 57-63
79. Nurieva R, Yang X O., Martinez G et al. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature 2007 448 7152 480-483 (Pubitemid 47123514)
80. Korn T, Bettelli E, Gao W et al. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 2007 448 7152 484-487 (Pubitemid 47123515)
81. Zhou L, Ivanov I I., Spolski R et al. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol 2007 8 9 967-974 (Pubitemid 47300011)
82. Nurieva R I., Chung Y, Martinez G J. et al. Bcl6 mediates the development of T follicular helper cells. Science 2009 325 5943 1001-1005
83. Zeng R, Spolski R, Finkelstein S E. et al. Synergy of IL-21 and IL-15 in regulating CD8 + T cell expansion and function. J Exp Med 2005 201 1 139-148 (Pubitemid 40130091)
84. Ozaki K, Spolski R, Feng C G. et al. A critical role for IL-21 in regulating immunoglobulin production. Science 2002 298 5598 1630-1634 (Pubitemid 35387203)
85. Jin H, Carrio R, Yu A, Malek T R. Distinct activation signals determine whether IL-21 induces B cell costimulation, growth arrest, or Bim-dependent apoptosis. J Immunol 2004 173 1 657-665 (Pubitemid 38797396)
86. Mehta D S., Wurster A L., Whitters M J., Young D A., Collins M, Grusby M J. IL-21 induces the apoptosis of resting and activated primary B cells. J Immunol 2003 170 8 4111-4118 (Pubitemid 36428174)
87. Ozaki K, Spolski R, Ettinger R et al. Regulation of B cell differentiation and plasma cell generation by IL-21, a novel inducer of Blimp-1 and Bcl-6. J Immunol 2004 173 9 5361-5371 (Pubitemid 39392119)
88. Herber D, Brown T P., Liang S, Young D A., Collins M, Dunussi-Joannopoulos K. IL-21 has a pathogenic role in a lupus-prone mouse model and its blockade with IL-21R.Fc reduces disease progression. J Immunol 2007 178 6 3822-3830 (Pubitemid 46417651)
89. Vollmer T L., Liu R, Price M, Rhodes S, La Cava A, Shi F D. Differential effects of IL-21 during initiation and progression of autoimmunity against neuroantigen. J Immunol 2005 174 5 2696-2701 (Pubitemid 40279684)
90. Oh I, Ozaki K, Meguro A et al. Altered effector CD4 + T cell function in IL-21R / CD4 + T cell-mediated graft-versus-host disease. J Immunol 2010 185 3 1920-1926
91. Morton L M., Purdue M P., Zheng T et al. Risk of non-Hodgkin lymphoma associated with germline variation in genes that regulate the cell cycle, apoptosis, and lymphocyte development. Cancer Epidemiol Biomarkers Prev 2009 18 4 1259-1270
92. Man K M., Drejet A, Keeffe E B., Garcia-Kennedy R, Imperial J C., Esquivel C O. Primary sclerosing cholangitis and Hodgkin's disease. Hepatology 1993 18 5 1127-1131 (Pubitemid 23320443)
93. Cholongitas E, Pipili C, Kaklamanis L, Dasenaki M. Is there any association between non-Hodgkin's lymphoma and primary sclerosing cholangitis/autoimmune hepatitis overlap syndrome? Dig Dis Sci 2008 53 3 867-868 (Pubitemid 351317063)
94. Strasser A. The role of BH3-only proteins in the immune system. Nat Rev Immunol 2005 5 3 189-200 (Pubitemid 40364821)
95. Bouillet P, Metcalf D, Huang D C. et al. Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science 1999 286 5445 1735-1738 (Pubitemid 129515880)
96. Hildeman D A., Zhu Y, Mitchell T C. et al. Activated T cell death in vivo mediated by proapoptotic bcl-2 family member bim. Immunity 2002 16 6 759-767 (Pubitemid 34786475)
97. Puthalakath H, O'Reilly L A., Gunn P et al. ER stress triggers apoptosis by activating BH3-only protein Bim. Cell 2007 129 7 1337-1349 (Pubitemid 46962086)
98. Satsangi J, Parkes M, Louis E et al. Two stage genome-wide search in inflammatory bowel disease provides evidence for susceptibility loci on chromosomes 3, 7 and 12. Nat Genet 1996 14 2 199-202 (Pubitemid 26338804)
99. Raelson J V., Little R D., Ruether A et al. Genome-wide association study for Crohn's disease in the Quebec Founder Population identifies multiple validated disease loci. Proc Natl Acad Sci U S A 2007 104 37 14747-14752 (Pubitemid 350003214)
100. Goyette P, Lefebvre C, Ng A et al. Gene-centric association mapping of chromosome 3p implicates MST1 in IBD pathogenesis. Mucosal Immunol 2008 1 2 131-138
101. Esworthy R S., Aranda R, Martin M G., Doroshow J H., Binder S W., Chu F F. Mice with combined disruption of Gpx1 and Gpx2 genes have colitis. Am J Physiol Gastrointest Liver Physiol 2001 281 3 G848-G855
102. Beckly J B., Hancock L, Geremia A et al. Two-stage candidate gene study of chromosome 3p demonstrates an association between nonsynonymous variants in the MST1R gene and Crohn's disease. Inflamm Bowel Dis 2008 14 4 500-507 (Pubitemid 351571829)
103. Hunt K A., Zhernakova A, Turner G et al. Newly identified genetic risk variants for celiac disease related to the immune response. Nat Genet 2008 40 4 395-402 (Pubitemid 351450876)
104. Yoshimura T, Yuhki N, Wang M H., Skeel A, Leonard E J. Cloning, sequencing, and expression of human macrophage stimulating protein (MSP, MST1) confirms MSP as a member of the family of kringle proteins and locates the MSP gene on chromosome 3. J Biol Chem 1993 268 21 15461-15468 (Pubitemid 23222036)
105. Wang M H., Skeel A, Leonard E J. Proteolytic cleavage and activation of pro-macrophage-stimulating protein by resident peritoneal macrophage membrane proteases. J Clin Invest 1996 97 3 720-727 (Pubitemid 26057091)
106. Bezerra J A., Carrick T L., Degen J L., Witte D, Degen S J. Biological effects of targeted inactivation of hepatocyte growth factor-like protein in mice. J Clin Invest 1998 101 5 1175-1183 (Pubitemid 28125297)
107. Gaudino G, Follenzi A, Naldini L et al. RON is a heterodimeric tyrosine kinase receptor activated by the HGF homologue MSP. EMBO J 1994 13 15 3524-3532 (Pubitemid 24246189)
108. Wang M H., Dlugosz A A., Sun Y, Suda T, Skeel A, Leonard E J. Macrophage-stimulating protein induces proliferation and migration of murine keratinocytes. Exp Cell Res 1996 226 1 39-46 (Pubitemid 26238925)
109. Wang M H., Ronsin C, Gesnel M C. et al. Identification of the ron gene product as the receptor for the human macrophage stimulating protein. Science 1994 266 5182 117-119 (Pubitemid 24345331)
110. Kurihara N, Iwama A, Tatsumi J, Ikeda K, Suda T. Macrophage-stimulating protein activates STK receptor tyrosine kinase on osteoclasts and facilitates bone resorption by osteoclast-like cells. Blood 1996 87 9 3704-3710 (Pubitemid 26129598)
111. Goyette P, Lefebvre C, Ng A et al. Gene-centric association mapping of chromosome 3p implicates MST1 in IBD pathogenesis. Mucosal Immunol 2008 1 2 131-138
112. Morrison A C., Wilson C B., Ray M, Correll P H. Macrophage-stimulating protein, the ligand for the stem cell-derived tyrosine kinase/RON receptor tyrosine kinase, inhibits IL-12 production by primary peritoneal macrophages stimulated with IFN-gamma and lipopolysaccharide. J Immunol 2004 172 3 1825-1832 (Pubitemid 38116831)
113. Chen Y Q., Fisher J H., Wang M H. Activation of the RON receptor tyrosine kinase inhibits inducible nitric oxide synthase (iNOS) expression by murine peritoneal exudate macrophages: phosphatidylinositol-3 kinase is required for RON-mediated inhibition of iNOS expression. J Immunol 1998 161 9 4950-4959 (Pubitemid 28492076)
114. Zhou Y Q., Chen Y Q., Fisher J H., Wang M H. Activation of the RON receptor tyrosine kinase by macrophage-stimulating protein inhibits inducible cyclooxygenase-2 expression in murine macrophages. J Biol Chem 2002 277 41 38104-38110 (Pubitemid 35154662)
115. Liu Q P., Fruit K, Ward J, Correll P H. Negative regulation of macrophage activation in response to IFN-gamma and lipopolysaccharide by the STK/RON receptor tyrosine kinase. J Immunol 1999 163 12 6606-6613
116. Correll P H., Iwama A, Tondat S, Mayrhofer G, Suda T, Bernstein A. Deregulated inflammatory response in mice lacking the STK/RON receptor tyrosine kinase. Genes Funct 1997 1 1 69-83
117. Lei X G., Cheng W H. New roles for an old selenoenzyme: evidence from glutathione peroxidase-1 null and overexpressing mice. J Nutr 2005 135 10 2295-2298 (Pubitemid 41429580)
118. Esworthy R S., Binder S W., Doroshow J H., Chu F F. Microflora trigger colitis in mice deficient in selenium-dependent glutathione peroxidase and induce Gpx2 gene expression. Biol Chem 2003 384 4 597-607 (Pubitemid 36609175)
119. Gao Q, Esworthy R S., Kim B W., Synold T W., Smith D D., Chu F F. Atherogenic diets exacerbate colitis in mice deficient in glutathione peroxidase. Inflamm Bowel Dis 2010 16 12 2043-2054
120. Todd D J., Lee A H., Glimcher L H. The endoplasmic reticulum stress response in immunity and autoimmunity. Nat Rev Immunol 2008 8 9 663-674
121. Kaser A, Lee A H., Franke A et al. XBP1 links ER stress to intestinal inflammation and confers genetic risk for human inflammatory bowel disease. Cell 2008 134 5 743-756
122. Fickert P, Zollner G, Fuchsbichler A et al. Effects of ursodeoxycholic and cholic acid feeding on hepatocellular transporter expression in mouse liver. Gastroenterology 2001 121 1 170-183 (Pubitemid 32591527)
123. Lee D H., Esworthy R S., Chu C, Pfeifer G P., Chu F F. Mutation accumulation in the intestine and colon of mice deficient in two intracellular glutathione peroxidases. Cancer Res 2006 66 20 9845-9851 (Pubitemid 44672035)
124. Chu F F., Esworthy R S., Chu P G. et al. Bacteria-induced intestinal cancer in mice with disrupted Gpx1 and Gpx2 genes. Cancer Res 2004 64 3 962-968 (Pubitemid 38176898)
125. Loh K, Deng H, Fukushima A et al. Reactive oxygen species enhance insulin sensitivity. Cell Metab 2009 10 4 260-272
126. Franke A, Balschun T, Karlsen T H. et al, IBSEN study group. Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. Nat Genet 2008 40 11 1319-1323
127. Hov J R., Keitel V, Laerdahl J K. et al, IBSEN Study Group. Mutational characterization of the bile acid receptor TGR5 in primary sclerosing cholangitis. PLoS ONE 2010 5 8 e12403
128. Hov J R., Keitel V, Laerdahl J K. et al, IBSEN Study Group. Mutational characterization of the bile acid receptor TGR5 in primary sclerosing cholangitis. PLoS ONE 2010 5 8 e12403
129. Kawamata Y, Fujii R, Hosoya M et al. A G protein-coupled receptor responsive to bile acids. J Biol Chem 2003 278 11 9435-9440 (Pubitemid 36800434)
130. Keitel V, Donner M, Winandy S, Kubitz R, H?ussinger D. Expression and function of the bile acid receptor TGR5 in Kupffer cells. Biochem Biophys Res Commun 2008 372 1 78-84 (Pubitemid 351778164)
131. Fiorucci S, Mencarelli A, Palladino G, Cipriani S. Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders. Trends Pharmacol Sci 2009 30 11 570-580
132. Watanabe M, Houten S M., Mataki C et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 2006 439 7075 484-489 (Pubitemid 43152840)
133. Thomas C, Gioiello A, Noriega L et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab 2009 10 3 167-177
134. Chhabra E S., Higgs H N. The many faces of actin: matching assembly factors with cellular structures. Nat Cell Biol 2007 9 10 1110-1121 (Pubitemid 47500485)
135. Pollard T D. Regulation of actin filament assembly by Arp2/3 complex and formins. Annu Rev Biophys Biomol Struct 2007 36 451-477 (Pubitemid 47007562)
136. Gournier H, Goley E D., Niederstrasser H, Trinh T, Welch M D. Reconstitution of human Arp2/3 complex reveals critical roles of individual subunits in complex structure and activity. Mol Cell 2001 8 5 1041-1052 (Pubitemid 34031806)
137. Robinson R C., Turbedsky K, Kaiser D A. et al. Crystal structure of Arp2/3 complex. Science 2001 294 5547 1679-1684 (Pubitemid 33104831)
138. Padrick S B., Rosen M K. Physical mechanisms of signal integration by WASP family proteins. Annu Rev Biochem 2010 79 707-735
139. Cai L, Marshall T W., Uetrecht A C., Schafer D A., Bear J E. Coronin 1B coordinates Arp2/3 complex and cofilin activities at the leading edge. Cell 2007 128 5 915-929 (Pubitemid 46341411)
140. Shiow L R., Roadcap D W., Paris K et al. The actin regulator coronin 1A is mutant in a thymic egress-deficient mouse strain and in a patient with severe combined immunodeficiency. Nat Immunol 2008 9 11 1307-1315
141. Cotta-de-Almeida V, Westerberg L, Maillard M H. et al. Wiskott Aldrich syndrome protein (WASP) and N-WASP are critical for T cell development. Proc Natl Acad Sci U S A 2007 104 39 15424-15429 (Pubitemid 47502933)
142. Maillard M H., Cotta-de-Almeida V, Takeshima F et al. The Wiskott-Aldrich syndrome protein is required for the function of CD4(+)CD25(+)Foxp3(+) regulatory T cells. J Exp Med 2007 204 2 381-391 (Pubitemid 46294553)
143. Nguyen D D., Maillard M H., Cotta-de-Almeida V et al. Lymphocyte-dependent and Th2 cytokine-associated colitis in mice deficient in Wiskott-Aldrich syndrome protein. Gastroenterology 2007 133 4 1188-1197 (Pubitemid 47494455)
144. Ramesh N, Geha R. Recent advances in the biology of WASP and WIP. Immunol Res 2009 44 1-3 99-111
145. Lambrechts A, Gevaert K, Cossart P, Vandekerckhove J, Van Troys M. Listeria comet tails: the actin-based motility machinery at work. Trends Cell Biol 2008 18 5 220-227
146. Waugh D J., Wilson C. The interleukin-8 pathway in cancer. Clin Cancer Res 2008 14 21 6735-6741
147. Stillie R, Farooq S M., Gordon J R., Stadnyk A W. The functional significance behind expressing two IL-8 receptor types on PMN. J Leukoc Biol 2009 86 3 529-543
148. Isse K, Harada K, Nakanuma Y. IL-8 expression by biliary epithelial cells is associated with neutrophilic infiltration and reactive bile ductules. Liver Int 2007 27 5 672-680 (Pubitemid 47097318)
149. Komori A, Nakamura M, Fujiwara S et al. Human intrahepatic biliary epithelial cell as a possible modulator of hepatic regeneration: Potential role of biliary epithelial cell for hepatic remodeling in vivo. Hepatol Res 2007 37 Suppl 3 S438-S443 (Pubitemid 47570657)
150. Balkwill F. Cancer and the chemokine network. Nat Rev Cancer 2004 4 7 540-550 (Pubitemid 38868623)
151. Agarwal A, Tressel S L., Kaimal R et al. Identification of a metalloprotease-chemokine signaling system in the ovarian cancer microenvironment: implications for antiangiogenic therapy. Cancer Res 2010 70 14 5880-5890
152. Baranzini S E., Wang J, Gibson R A. et al. Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Hum Mol Genet 2009 18 4 767-778
153. Comabella M, Craig D W., Camia-Tato M et al, BiomarkerMS Study Group. Identification of a novel risk locus for multiple sclerosis at 13q31.3 by a pooled genome-wide scan of 500,000 single nucleotide polymorphisms. PLoS ONE 2008 3 10 e3490
154. Cnit M D., Blanco-Kelly F, de las Heras V et al. Glypican 5 is an interferon-beta response gene: a replication study. Mult Scler 2009 15 8 913-917
155. Okada Y, Kamatani Y, Takahashi A et al. A genome-wide association study in 19 633 Japanese subjects identified LHX3-QSOX2 and IGF1 as adult height loci. Hum Mol Genet 2010 19 11 2303-2312
156. Calboli F C., Tozzi F, Galwey N W. et al. A genome-wide association study of neuroticism in a population-based sample. PLoS ONE 2010 5 7 e11504
157. Lesch K P., Timmesfeld N, Renner T J. et al. Molecular genetics of adult ADHD: converging evidence from genome-wide association and extended pedigree linkage studies. J Neural Transm 2008 115 11 1573-1585
158. Li Y, Sheu C C., Ye Y et al. Genetic variants and risk of lung cancer in never smokers: a genome-wide association study. Lancet Oncol 2010 11 4 321-330
159. Pelak K, Goldstein D B., Walley N M. et al, Infectious Disease Clinical Research Program HIV Working Group National Institute of Allergy and Infectious Diseases Center for HIV/AIDS Vaccine Immunology (CHAVI). Host determinants of HIV-1 control in African Americans. J Infect Dis 2010 201 8 1141-1149
160. Filmus J, Capurro M, Rast J. Glypicans. Genome Biol 2008 9 5 224
161. Veugelers M, Vermeesch J, Reekmans G, Steinfeld R, Marynen P, David G. Characterization of glypican-5 and chromosomal localization of human GPC5, a new member of the glypican gene family. Genomics 1997 40 1 24-30 (Pubitemid 27108243)
162. Saunders S, Paine-Saunders S, Lander A D. Expression of the cell surface proteoglycan glypican-5 is developmentally regulated in kidney, limb, and brain. Dev Biol 1997 190 1 78-93 (Pubitemid 27444739)
163. Veugelers M, De Cat B, Ceulemans H et al. Glypican-6, a new member of the glypican family of cell surface heparan sulfate proteoglycans. J Biol Chem 1999 274 38 26968-26977
164. Paine-Saunders S, Viviano B L., Saunders S. GPC6, a novel member of the glypican gene family, encodes a product structurally related to GPC4 and is colocalized with GPC5 on human chromosome 13. Genomics 1999 57 3 455-458 (Pubitemid 29239237)
165. Campos-Xavier A B., Martinet D, Bateman J et al. Mutations in the heparan-sulfate proteoglycan glypican 6 (GPC6) impair endochondral ossification and cause recessive omodysplasia. Am J Hum Genet 2009 84 6 760-770
166. Gregersen P K., Amos C I., Lee A T. et al. REL, encoding a member of the NF-kappaB family of transcription factors, is a newly defined risk locus for rheumatoid arthritis. Nat Genet 2009 41 7 820-823
167. Dubois P C., Trynka G, Franke L et al. Multiple common variants for celiac disease influencing immune gene expression. Nat Genet 2010 42 4 295-302
168. McGovern D P., Gardet A, Törkvist L et al, NIDDK IBD Genetics Consortium. Genome-wide association identifies multiple ulcerative colitis susceptibility loci. Nat Genet 2010 42 4 332-337
169. Vallabhapurapu S, Karin M. Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol 2009 27 693-733
170. Liou H C., Hsia C Y. Distinctions between c-Rel and other NF-kappaB proteins in immunity and disease. Bioessays 2003 25 8 767-780 (Pubitemid 36966377)
171. Hilliard B A., Mason N, Xu L et al. Critical roles of c-Rel in autoimmune inflammation and helper T cell differentiation. J Clin Invest 2002 110 6 843-850
172. Köntgen F, Grumont R J., Strasser A et al. Mice lacking the c-rel proto-oncogene exhibit defects in lymphocyte proliferation, humoral immunity, and interleukin-2 expression. Genes Dev 1995 9 16 1965-1977
173. Long M, Park S G., Strickland I, Hayden M S., Ghosh S. Nuclear factor-kappaB modulates regulatory T cell development by directly regulating expression of Foxp3 transcription factor. Immunity 2009 31 6 921-931
174. Rao S, Gerondakis S, Woltring D, Shannon M F. c-Rel is required for chromatin remodeling across the IL-2 gene promoter. J Immunol 2003 170 7 3724-3731 (Pubitemid 36359242)
175. Chen G, Hardy K, Bunting K, Daley S, Ma L, Shannon M F. Regulation of the IL-21 gene by the NF-kappaB transcription factor c-Rel. J Immunol 2010 185 4 2350-2359
176. Grossmann M, O'Reilly L A., Gugasyan R, Strasser A, Adams J M., Gerondakis S. The anti-apoptotic activities of Rel and RelA required during B-cell maturation involve the regulation of Bcl-2 expression. EMBO J 2000 19 23 6351-6360
177. Pohl T, Gugasyan R, Grumont R J. et al. The combined absence of NF-kappa B1 and c-Rel reveals that overlapping roles for these transcription factors in the B cell lineage are restricted to the activation and function of mature cells. Proc Natl Acad Sci U S A 2002 99 7 4514-4519 (Pubitemid 34286016)
178. Gieling R G., Elsharkawy A M., Caamao J H. et al. The c-Rel subunit of nuclear factor-kappaB regulates murine liver inflammation, wound-healing, and hepatocyte proliferation. Hepatology 2010 51 3 922-931
179. Raychaudhuri S, Plenge R M., Rossin E J. et al, International Schizophrenia Consortium. Identifying relationships among genomic disease regions: predicting genes at pathogenic SNP associations and rare deletions. PLoS Genet 2009 5 6 e1000534
180. Mamanova L, Coffey A J., Scott C E. et al. Target-enrichment strategies for next-generation sequencing. Nat Methods 2010 7 2 111-118
181. Melum E, May S, Schilhabel M B. et al. SNP discovery performance of two second-generation sequencing platforms in the NOD2 gene region. Hum Mutat 2010 31 7 875-885
182. Kaser A, Zeissig S, Blumberg R S. Inflammatory bowel disease. Annu Rev Immunol 2010 28 573-621
183. Probert C S., Christ A D., Saubermann L J. et al. Analysis of human common bile duct-associated T cells: evidence for oligoclonality, T cell clonal persistence, and epithelial cell recognition. J Immunol 1997 158 4 1941-1948 (Pubitemid 127469554)
184. Broom? U, Grunewald J, Scheynius A, Olerup O, Hultcrantz R. Preferential V beta3 usage by hepatic T lymphocytes in patients with primary sclerosing cholangitis. J Hepatol 1997 26 3 527-534 (Pubitemid 27112717)
185. Graziadei I W., Wiesner R H., Batts K P. et al. Recurrence of primary sclerosing cholangitis following liver transplantation. Hepatology 1999 29 4 1050-1056 (Pubitemid 29168735)
186. Kugelmas M, Spiegelman P, Osgood M J. et al. Different immunosuppressive regimens and recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl 2003 9 7 727-732 (Pubitemid 36874461)
187. Liu J O. Calmodulin-dependent phosphatase, kinases, and transcriptional corepressors involved in T-cell activation. Immunol Rev 2009 228 1 184-198
188. Todd J A. Etiology of type 1 diabetes. Immunity 2010 32 4 457-467
189. Tang Q, Adams J Y., Penaranda C et al. Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity 2008 28 5 687-697
190. Nejentsev S, Walker N, Riches D, Egholm M, Todd J A. Rare variants of IFIH1, a gene implicated in antiviral responses, protect against type 1 diabetes. Science 2009 324 5925 387-389
191. Smyth D J., Cooper J D., Bailey R et al. A genome-wide association study of nonsynonymous SNPs identifies a type 1 diabetes locus in the interferon-induced helicase (IFIH1) region. Nat Genet 2006 38 6 617-619 (Pubitemid 43927300)
192. Kato H, Takeuchi O, Sato S et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 2006 441 7089 101-105
193. Dotta F, Censini S, van Halteren A G. et al. Coxsackie B4 virus infection of beta cells and natural killer cell insulitis in recent-onset type 1 diabetic patients. Proc Natl Acad Sci U S A 2007 104 12 5115-5120 (Pubitemid 47186185)
194. Boberg K M., Bergquist A, Mitchell S et al. Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation. Scand J Gastroenterol 2002 37 10 1205-1211 (Pubitemid 35189610)
195. Donaldson P T., Norris S. Evaluation of the role of MHC class II alleles, haplotypes and selected amino acid sequences in primary sclerosing cholangitis. Autoimmunity 2002 35 8 555-564 (Pubitemid 36321898)
196. Donaldson P T., Norris S. Immunogenetics in PSC. Best Pract Res Clin Gastroenterol 2001 15 4 611-627 (Pubitemid 32747014)
197. Zhao B, Schlesiger C, Masucci M G., Lindsten K. The ubiquitin specific protease 4 (USP4) is a new player in the Wnt signalling pathway. J Cell Mol Med 2009 13 8B 1886-1895
198. Zhou Q, Hennenberg M, Trebicka J et al. Intrahepatic upregulation of RhoA and Rho-kinase signalling contributes to increased hepatic vascular resistance in rats with secondary biliary cirrhosis. Gut 2006 55 9 1296-1305 (Pubitemid 44277362)
199. Debruyne P R., Bruyneel E A., Karaguni I M. et al. Bile acids stimulate invasion and haptotaxis in human colorectal cancer cells through activation of multiple oncogenic signaling pathways. Oncogene 2002 21 44 6740-6750 (Pubitemid 35221916)
200. Applegarth D A., Toone J R. Glycine encephalopathy (nonketotic hyperglycinaemia): review and update. J Inherit Metab Dis 2004 27 3 417-422 (Pubitemid 38756325)
201. Barresi R, Campbell K P. Dystroglycan: from biosynthesis to pathogenesis of human disease. J Cell Sci 2006 119 Pt 2 199-207 (Pubitemid 43210689)
202. Zanazzi G, Matthews G. The molecular architecture of ribbon presynaptic terminals. Mol Neurobiol 2009 39 2 130-148
203. Fujino T, Watanabe K, Beppu M, Kikugawa K, Yasuda H. Identification of oxidized protein hydrolase of human erythrocytes as acylpeptide hydrolase. Biochim Biophys Acta 2000 1478 1 102-112 (Pubitemid 30136143)
204. Correll P H., Morrison A C., Lutz M A. Receptor tyrosine kinases and the regulation of macrophage activation. J Leukoc Biol 2004 75 5 731-737 (Pubitemid 38580051)
205. Daig R, Andus T, Aschenbrenner E, Falk W, Schölmerich J, Gross V. Increased interleukin 8 expression in the colon mucosa of patients with inflammatory bowel disease. Gut 1996 38 2 216-222
206. Buanne P, Di Carlo E, Caputi L et al. Crucial pathophysiological role of CXCR2 in experimental ulcerative colitis in mice. J Leukoc Biol 2007 82 5 1239-1246 (Pubitemid 350133522)
207. Hsing A W., Sakoda L C., Rashid A et al. Variants in inflammation genes and the risk of biliary tract cancers and stones: a population-based study in China. Cancer Res 2008 68 15 6442-6452
208. Dupuis-Girod S, Medioni J, Haddad E et al. Autoimmunity in Wiskott-Aldrich syndrome: risk factors, clinical features, and outcome in a single-center cohort of 55 patients. Pediatrics 2003 111 5 Pt 1 e622-e627
209. Kahn K, Sharp H, Hunter D, Kerzner B, Jessurun J, Blaese M. Primary sclerosing cholangitis in Wiskott-Aldrich syndrome. J Pediatr Gastroenterol Nutr 2001 32 1 95-99 (Pubitemid 32094507)
210. Keitel V, Cupisti K, Ullmer C, Knoefel W T., Kubitz R, Hussinger D. The membrane-bound bile acid receptor TGR5 is localized in the epithelium of human gallbladders. Hepatology 2009 50 3 861-870
211. Bielig H, Zurek B, Kutsch A et al. A function for AAMP in Nod2-mediated NF-kappaB activation. Mol Immunol 2009 46 13 2647-2654
212. Hu L, Smith T F., Goldberger G. LFG: a candidate apoptosis regulatory gene family. Apoptosis 2009 14 11 1255-1265
213. Zhao H, Ito A, Sakai N, Matsuzawa Y, Yamashita S, Nojima H. RECS1 is a negative regulator of matrix metalloproteinase-9 production and aged RECS1 knockout mice are prone to aortic dilation. Circ J 2006 70 5 615-624